We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evolving treatment options of myelodysplastic syndromes.
- Authors
Verbeek, W.; Ganser, A.
- Abstract
Myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid stem cell disorders characterized by peripheral cytopenias and dysplasia of bone marrow progenitor cells. A clonal evolution can result in progressive bone marrow failure and transformation towards acute myelogenous leukemia. A patient's prognosis as estimated by the International Prognostic Scoring System, age, and co-morbidities have to be considered for the selection of various treatment options. Although supportive care remains standard therapy for low-risk MDS, a number of treatment approaches that aim to improve cytopenia in transfusion-dependent patients are currently under investigation. Among others, immunosuppressive, anticytokine, and antiangiogenic therapy will be discussed. The demethylating agents 5-azacytidine and decitabine are promising for the treatment of elderly patients with high-risk MDS. An increase of the upper age limit for allogeneic stem cell transplantation, the only curative treatment option, by the development of dose-reduced conditioning regimens may have implications for the treatment of MDS patients in the future.
- Subjects
MYELODYSPLASTIC syndromes; DYSPLASIA; CELLULAR therapy; IMMUNE system; ACUTE myeloid leukemia; MYELOID leukemia
- Publication
Annals of Hematology, 2001, Vol 80, Issue 9, p499
- ISSN
0939-5555
- Publication type
journal article
- DOI
10.1007/s002770100347